You are subscribed to one of the following page update alerts:
Vaccine Code Set Update Publication Date: August 26, 2021
The individual filenames included in this distribution contain the publication date (20210824)
Release Notes: This release includes updates for all vaccine codes except Vaccine Information Statement (VIS) codes and maps.
Release notes are designed as a guide to highlight changes that have been made to the vaccine codes since the last publication. They should not be used as the primary source of code information. The vaccine code files themselves should be utilized.
General Note Regarding This Release: Codes with “Last Update” dates from July 30, 2021 to August 24, 2021 reflect the changes and additions in this release. This is a large release and includes the following code set updates:
- Vaccine Code Set Updates Not Related to COVID-19
- New and Retired Codes for Seasonal Influenza Vaccines
- Other Vaccine Code Additions and Changes
- COVID-19 Related Code Updates
- Pfizer U.S. COVID-19 BLA Approval
- Other COVID-19 Related Code Changes
Vaccine Code Set Updates
- Vaccine Code Updates Not Related to COVID-19
- New 2021/2022 Seasonal Influenza Vaccines: The final vaccine codes for the 2021/2022 seasonal influenza vaccines have been added as shown in Table 1 below. Also updated is the website table “2021/2022 Seasonal Influenza Codes and Crosswalk” that now includes all seasonal vaccines. The table is available on the CDC website table using the following link: https://www.cdc.gov/vaccines/programs/iis/code-sets.html
Note that the Fluad trivalent product will not be provided for the 2021/2022 season.
Table 1: Seasonal Influenza NDCs Added for the 2021/2022 Seasonal Influenza Season| Sale Proprietary Name | Sale Labeler | Unit of Sale NDC11 | Unit of Use NDC11 | Presentation | CVX Code | MVX Code |
|---|
FluMist Quadrivalent | MedImmune, LLC | 66019-0308-10 | 66019-0308-01 | APPLICATOR .2 mL | 149 | MED |
|---|
Afluria Quadrivalent | Seqirus PTY LTD. | 33332-0321-01 | 33332-0321-02 | SYRINGE, .5 mL | 150 | SEQ |
|---|
Afluria Quadrivalent | Seqirus PTY LTD. | 33332-0421-10 | 33332-0421-11 | VIAL, 5 mL, MULTI-DOSE | 158 | SEQ |
|---|
Afluria Quadrivalent | Seqirus PTY LTD. | 33332-0221-20 | 33332-0221-21 | SYRINGE, .25 ML | 161 | SEQ |
|---|
- Retired 2020/2021 Seasonal Influenza NDCs:Table 2 below identifies the influenza vaccine NDC codes that have been retired from the 2020/2021 season in this code release.
Table 2: 2020/2021 Seasonal Influenza NDCs Retired
Sale Proprietary Name | Sale Labeler | Unit of Sale NDC11 | Unit of Use NDC11 |
|---|
Afluria Quadrivalent | Seqirus Pty Ltd. | 33332-0320-01 | 33332-0320-02 |
|---|
Afluria Quadrivalent | Seqirus Pty Ltd. | 33332-0420-10 | 33332-0420-11 |
|---|
Afluria Quadrivalent | Seqirus Pty Ltd. | 33332-0220-20 | 33332-0220-21 |
|---|
FLUAD | Seqirus, Inc. | 70461-0020-03 | 70461-0020-04 |
|---|
- Other Vaccine Code Additions and Changes
Non-Influenza Vaccine NDCs Added: The following new PCV 15 valent and PCV 20 valent vaccine NDCs have been added. See Table 3 below.
Table 3: New PCV Vaccine NDCs
Sale Proprietary Name | Sale Labeler | Unit of Sale NDC11 | Unit of Use NDC11 | CVX Code | MVX Code |
|---|
Prevnar 20 | Wyeth Pharmaceutical Division of Wyeth Holdings LLC | 00005-2000-10 | 00005-2000-01 | 216 | PFR |
|---|
Prevnar 20 | Wyeth Pharmaceutical Division of Wyeth Holdings LLC | 00005-2000-02 | 00005-2000-01 | 216 | PFR |
|---|
VAXNEUVANCE | Merck Sharp & Dohme Corp. | 00006-4329-03 | 00006-4329-01 | 215 | MSD |
|---|
VAXNEUVANCE | Merck Sharp & Dohme Corp. | 00006-4329-02 | 00006-4329-01 | 215 | MSD |
|---|
At this time, there are no associated CPT codes or Vaccine Information Statements (VIS) available.
The following new CVX codes have been added to support the new PCV 15-valent and PCV 20-valent products. See Table 3.1 below.
Table 3.1: New PCV CVX Codes
CVX Code | Description | Short Name | CVX Status |
|---|
215 | Pneumococcal conjugate vaccine 15-valent (PCV15), polysaccharide CRM197 conjugate, adjuvant, preservative free | Pneumococcal conjugate PCV15, polysaccharide CRM197 conjugate, adjuvant, PF | Active |
|---|
216 | Pneumococcal conjugate vaccine 20-valent (PCV20), polysaccharide CRM197 conjugate, adjuvant, preservative free | Pneumococcal conjugate PCV20, polysaccharide CRM197 conjugate, adjuvant, PF | Active |
|---|
The following Product / Tradename additions have been made to support the new PCV 15-valent and PCV 20-valent products. See Table 3.2 below.
Table 3.2: New Product Tradename/MVX Codes
Product/Tradename | Manufacturer | MVX | Notes |
|---|
VAXNEUVANCE | Merck and Co., Inc. | MSD | New vaccine product tradename effective 8/1/2021 |
|---|
PREVNAR 20 | Pfizer, Inc | PFR | New product effective 8/13/2021 |
|---|
No new MVX Codes have been added
MVX Code Changes: The following additional manufacturer MVX code additions and updates have been made.
- A minor typographical correction has been made to the following MVX record
PAX | Emergent Travel Health, Inc (Formerly PaxVax) | Emergent Biosolutions acquired PaxVax 8/2021, U.S. vaccines starting to label under Emergent Travel Health Inc. |
|---|
- COVID-19 Related Code Updates
- Pfizer U.S. COVID-19 BLA Approval: The CDC Product Tradename table has been updated to reflect the Pfizer FDA BLA license approval and the introduction of the COMIRNATY Tradename to the U.S. market. No other code set changes relating to the BLA license have been made at this time.
| Product Tradename(s) | CVX Code | MVX Code |
|---|
Pfizer-BioNTech COVID-19 Vaccine (COMIRNATY) | 208 | PFR |
|---|
- Other COVID-19 Related Code Changes:
- AstraZeneca Covid-19 NDCs were temporarily inactivated in the release of 7/30/2021. The CVX code 210 was disassociated from the NDCs in this release. The MVX and product table associations continue.
- Novavax COVID-19 vaccine NDC codes have been temporarily inactivated pending U.S. regulatory submission and FDA review. The end dates for Unit of Sale NDC11 80631-0100-10 and Unit of Use NDC11 80631-0100-01 have been set to 8/1/2021. The MVX and product table associations continue. The following changes have also been made:
- CVX Code 211 for Novavax COVID-19 vaccine; status has been changed to “Pending” from “active” to reflect that this vaccine is currently not authorized or available in any market until a later date.
